Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder

Fineline Cube Jan 13, 2026
Company Drug

BMS’s Camzyos Meets Primary Endpoint in Phase III SCOUT-HCM Study for Adolescent oHCM

Fineline Cube Jan 13, 2026
Company Deals Medical Device

We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface

Fineline Cube Feb 21, 2023

We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...

Company Deals

Hybio Pharma and CR Medicine Collaborate on Market Expansion

Fineline Cube Feb 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot...

Company Drug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

Fineline Cube Feb 21, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...

Company Drug

Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy

Fineline Cube Feb 21, 2023

Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...

Company Drug

Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023

Fineline Cube Feb 21, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...

Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Company Deals

Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development

Fineline Cube Feb 21, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...

Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Policy / Regulatory

CDE Issues Guidelines for Real-World Drug Research and Evidence Framework

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) has released two important documents: the “Guiding Principles of...

Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Company Drug

Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study

Fineline Cube Feb 20, 2023

China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...

Company Deals

Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China

Fineline Cube Feb 20, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...

Company Deals

Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion

Fineline Cube Feb 20, 2023

China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with...

Company Deals R&D

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

Fineline Cube Feb 20, 2023

MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over...

Drug Policy / Regulatory

Zhejiang Suspends Generic Nesina Trading Due to IP Disputes

Fineline Cube Feb 20, 2023

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...

Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Posts pagination

1 … 503 504 505 … 608

Recent updates

  • Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share
  • FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder
  • AbbVie Commits $100 Billion US Investment and TrumpRx Expansion for Tariff Relief
  • Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation
  • BMS’s Camzyos Meets Primary Endpoint in Phase III SCOUT-HCM Study for Adolescent oHCM
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Company Drug

FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder

Company

AbbVie Commits $100 Billion US Investment and TrumpRx Expansion for Tariff Relief

Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.